Virtual Library

Start Your Search

Joseph Arturo Pinto



Author of

  • +

    P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 964)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.15-07 - Lung Cancer in the Young (ID 14248)

      16:45 - 18:00  |  Author(s): Joseph Arturo Pinto

      • Abstract
      • Slides

      Background

      Lung cancer is the leading cause of cancer related death worldwide. Median age at diagnosis is 70 years. Its presentation in patients 40 or younger is uncommon and it has been proposed that maybe is a different disease due to its clinical characteristics and genetic makeup. There are a limited number of studies in this population and they report different clinico-pathological characteristics in comparison with older patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      This is a retrospective analysis of patients 40 years or younger diagnosed with lung cancer between 2009 and 2015 at Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru. Patient characteristics such as age, sex, smoking history, family history, symptoms, histological type, stage at diagnosis, and overall survival were collected from clinical files.

      4c3880bb027f159e801041b1021e88e8 Result

      During the study period, we identified 2946 patients with lung cancer. Among these, 107 (3.63%) patients were 40 years or younger. Median age at diagnosis was 36 years and 58% of patients were female. Most patients (77.5%) lacked family history of cancer. A smoking history was present in 13.3% of patients and exposition to biomass fumes from inhouse cooking was reported in 16.3%. Mean time from onset of symptoms to diagnosis was 2 months. Frequent symptoms at diagnosis were cough (59.2%), weight loss (56.1%), chest pain (50%), dyspnea (44.2%), hemoptysis (18.4%) and fever (9.6%). Most patients (59.8%) had performance status (PS) of 1. Adenocarcinoma was the most histological type (64.5%), followed by not otherwise specified (NOS) lung cancer (13.1%), squamous carcinoma (10.3%) and neuroendocrine carcinoma (5.6%). Almost all patients (96.9%) had unresectable disease at diagnosis (7.3%, stage III; 89.6% stage IV). The median overall survival was 7 months (range 4.4 – 9.5).

      8eea62084ca7e541d918e823422bd82e Conclusion

      The proportion of young patients with lung cancer in our population is higher than that reported in the literature. Lung cancer in the young is mostly sporadic, more frequent in women and usually of adenocarcinoma type. Young patients tend to present with advanced disease at diagnosis, resulting in a very poor survival. The molecular characterization of this cohort of patients is ongoing.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.